Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

IMCR – Immunocore Holdings plc ADR

Immunocore Holdings plc
IMCR
$32.99
Name : Immunocore Holdings plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,657,206,528.00
EPSttm : -0.43
finviz dynamic chart for IMCR
Immunocore Holdings plc
$32.99
0.67%
$0.22

Float Short %

17.36

Margin Of Safety %

-20

Put/Call OI Ratio

3.04

EPS Next Q Diff

-0.32

EPS Last/This Y

0.36

EPS This/Next Y

-0.52

Price

32.99

Target Price

62.92

Analyst Recom

1.67

Performance Q

9.42

Relative Volume

0.99

Beta

0.77

Ticker: IMCR




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04IMCR33.023.300.0014580
2025-07-07IMCR32.473.300.2014580
2025-07-08IMCR33.283.360.0014784
2025-07-09IMCR34.623.340.0014805
2025-07-10IMCR35.473.340.0014805
2025-07-11IMCR35.023.341.0014804
2025-07-14IMCR35.313.340.0014804
2025-07-15IMCR35.23.350.3314800
2025-07-16IMCR35.833.351.0014797
2025-07-17IMCR36.233.350.5014804
2025-07-18IMCR36.363.350.5014804
2025-07-21IMCR36.933.350.5014804
2025-07-22IMCR36.752.080.009432
2025-07-23IMCR36.222.080.009432
2025-07-24IMCR35.282.080.009433
2025-07-25IMCR35.222.080.009433
2025-07-28IMCR33.992.080.099435
2025-07-29IMCR33.792.073000.009441
2025-07-30IMCR33.53.050.1312442
2025-07-31IMCR32.683.050.1312442
2025-08-01IMCR33.053.04416.6712448
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04IMCR33.024.2-42.5-0.66
2025-07-07IMCR32.464.2-40.9-0.66
2025-07-08IMCR33.284.2-43.7-0.66
2025-07-09IMCR34.584.2-44.4-0.66
2025-07-10IMCR35.454.2-43.5-0.66
2025-07-11IMCR35.024.2-42.8-0.66
2025-07-14IMCR35.304.2-42.5-0.66
2025-07-15IMCR35.154.2-41.8-0.66
2025-07-16IMCR35.684.2-42.9-0.66
2025-07-17IMCR36.214.2-42.7-0.66
2025-07-18IMCR36.294.2-42.1-0.66
2025-07-21IMCR36.944.2-43.0-0.66
2025-07-22IMCR37.214.2-42.4-0.66
2025-07-23IMCR36.0512.4-40.2-0.66
2025-07-24IMCR35.2712.4-40.7-0.66
2025-07-25IMCR35.1712.4-41.8-0.66
2025-07-28IMCR33.9929.5-39.9-0.60
2025-07-29IMCR33.9129.5-41.9-0.60
2025-07-30IMCR33.5029.5-41.2-0.60
2025-07-31IMCR32.7729.5-40.5-0.60
2025-08-01IMCR32.9910.2-42.2-0.66
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04IMCR106.475.1117.20
2025-07-07IMCR106.475.1117.20
2025-07-08IMCR106.475.1117.20
2025-07-09IMCR106.475.1117.20
2025-07-10IMCR106.475.1117.20
2025-07-11IMCR106.475.1117.46
2025-07-14IMCR106.475.1117.46
2025-07-15IMCR106.475.1117.46
2025-07-16IMCR106.475.1117.46
2025-07-17IMCR106.475.1117.46
2025-07-18IMCR106.475.1117.46
2025-07-21IMCR106.475.0817.46
2025-07-22IMCR107.185.0817.46
2025-07-23IMCR107.185.0817.46
2025-07-24IMCR107.185.0817.46
2025-07-25IMCR107.185.0817.36
2025-07-28IMCR107.184.8017.36
2025-07-29IMCR107.184.8017.36
2025-07-30IMCR107.184.8017.36
2025-07-31IMCR107.184.8017.36
2025-08-01IMCR107.184.8017.36
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.1

Avg. EPS Est. Current Quarter

-0.22

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

107.18

Institutional Transactions

4.8

Beta

0.77

Average Sales Estimate Current Quarter

92

Average Sales Estimate Next Quarter

96

Fair Value

26.38

Quality Score

53

Growth Score

55

Sentiment Score

6

Actual DrawDown %

57.1

Max Drawdown 5-Year %

Target Price

62.92

P/E

Forward P/E

PEG

P/S

4.96

P/B

4.4

P/Free Cash Flow

63.55

EPS

-0.44

Average EPS Est. Cur. Y​

-0.66

EPS Next Y. (Est.)

-1.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6.38

Relative Volume

0.99

Return on Equity vs Sector %

-29.5

Return on Equity vs Industry %

-10.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

-42.2
Immunocore Holdings plc
Sector: Healthcare
Industry: Biotechnology
Employees: 493
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
stock quote shares IMCR – Immunocore Holdings plc ADR Stock Price stock today
news today IMCR – Immunocore Holdings plc ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMCR – Immunocore Holdings plc ADR yahoo finance google finance
stock history IMCR – Immunocore Holdings plc ADR invest stock market
stock prices IMCR premarket after hours
ticker IMCR fair value insiders trading